The effect of intravitreal bevacizumab in the treatment of coats disease in children

Retina

Volumn 30, Issue 4, 2010, Pages 617-622

  Lin, Chun Ju ^a   Hwang, Jiunn Feng ^a   Chen, Yan Ting ^a   Chen, San Ni ^a,b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Coats disease in children; Intravitreal bevacizumab treatment

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB; TRIAMCINOLONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; B SCAN; CASE REPORT; CHILD; CLINICAL TRIAL; CRYOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EXUDATIVE RETINITIS; EYE DISEASE; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INFANT; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SCHOOL CHILD; SUBRETINAL FLUID; TELANGIECTASIA; VISUAL ACUITY; WATER ABSORPTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHILD; DRUG ADMINISTRATION ROUTES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; RETINAL DISEASES; RETINAL VESSELS; TELANGIECTASIS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 77951173410     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c2e0b7     Document Type: Article

References (22)

1. Coats' G. Forms of retinal diseases with massive exudation. R Lond Ophthalmol Hosp Rep 1908;17:440-525.
2. Black GC, Perveen R, Bonshek R, et al. Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet 1999;8:2031-2035.
3. Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats' disease: the 2000 Proctor Lecture. Am J Ophthalmol 2001;131:572-583.
4. Lai CH, Kuo HK, Wu PC, Kuo ML, Chen YJ. Manifestation of Coats' disease by age in Taiwan. Clin Experiment Ophthalmol 2007;35:361-365.
5. Mrejen S, Metge F, Denton E, Dureau P, Edelson C, Caputo G. Management of retinal detachment in Coats' disease: study of 15 cases. Retina 2008;28:S26-S32.
6. Schefler AC, Berrocal AM, Murray TG. Advanced Coats' disease: management with repetitive aggressive laser ablation therapy. Retina 2008;28:S38-S41.
7. Budning AS, Heon E, Gallie BL. Visual prognosis of Coats' disease. J AAPOS 1998;2:356-359.
8. Silodor SW, Augsburger JJ, Shields JA, Tasman W. Natural history and management of advanced Coats' disease. Ophthalmic Surg 1988;19:89-93.
9. Adam RS, Kertes PJ, Lam WC. Observations on the management of Coats' disease: less is more. Br J Ophthalmol 2007; 91:303-306.
10. Tripathi R, Ashton N. Electron microscopical study of Coat's disease. Br J Ophthalmol 1971;55:289-301.
11. Bergstrom CS, Hubbard GB. Combination intravitreal triamcinolone injection and cryotherapy for exudative retinal detachments in severe Coats' disease. Retina 2008;28:S33-S37.
12. Sun Y, Jain A, Moshfeghin DM. Elevated vascular endothelial growth factor levels in Coats' disease: rapid response to pegaptanib sodium. Graefe's Arch Clin Exp Ophthalmol 2007; 245:1387-1388.
13. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
14. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27: 141-149.
15. Venkatesh P, Mandal S, Garg S. Management of Coats' disease with bevacizumab in 2 patients. Can J Ophthalmol 2008; 43:245-246.
16. Alvarez-Rivera LG, Abraham-Marín ML, Flores-Orta HJ, Mayorquín-Ruiz M, Cortés-Luna CF. Coat's disease treated with bevacizumab (Avastin). Arch Soc Esp Oftalmol 2008;83: 329-331.
17. Cakir M, CekiçO, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats' disease. J AAPOS 2008;12:309-311.
18. Stergiou PK, Symeonidis C, Dimitrakos SA. Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol 2009;87:687-688.
19. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008; 28(Suppl):S13-S18.
20. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez- Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28(Suppl):S19-S25.
21. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez- Rojas ML, Salazar-Teran N, Chan RV. Reply. Retina 2009; 29:284-285.
22. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-164.